Investors

2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80.

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact: